

RECEIVED
CENTRAL FAX CENTER

PATENT CASE: CV01185K1BK

JAN 12 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

S. Chackalamannil et al

Serial No.: 10/671,216

Filed: 09/25/2003

For: "Thrombin Receptor Antagonists"

Examiner: Rita J. Desai

Group Art Unit: 1625

Atty. Docket No.: CV01185K1BK

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450**TERMINAL DISCLAIMER**

Sir:

Petitioner, Schering Corporation, is the owner of 100% interest in the instant application. Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 36 U.S.C. sections 154 to 156 and 173, as presently shortened by any terminal disclaimer, of commonly-owned U.S. Patent Application, Serial No. 10/457,256. Petitioner hereby agrees that any patent granted on the instant application shall be enforceable only for and during such period that it and any of the aforesaid patent application are commonly-owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the fully statutory term as defined in 35 U.S.C. sections 154 to 156 and 173 of the aforesaid patent application, as presently shortened by any terminal disclaimer, in the event that either one or both later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Petitioner is the owner of 100% interest in the instant application by virtue of an assignment to Schering Corporation from all the inventors, which

BEST AVAILABLE COPY

2

Case No. CV01185K1BK US


was recorded on September 10, 2001 in the U.S. Patent and Trademark Office at Reel 012158, Frame 0193.

The undersigned Attorney of Record states that he is empowered to act on behalf of the petitioner.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the instant or aforesaid applications or any patents issued thereon.

The USPTO is hereby authorized to charge the \$130 fee under 37 C.F.R. §1.20(d) for the present Terminal Disclaimer to charge account 19-0365. A duplicate of this document is enclosed for your records.

January 12, 2005
Schering-Plough Corporation
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, New Jersey 07033
Tel: 908-298-2960
Fax: 908-298-5388

Respectfully submitted,

Gerard E. Reinhardt
Reg. No. 43,041
Attorney for Applicant

49068-1

DUPLICATE

PATENT CASE: CV01185K1BK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**RECEIVED
CENTRAL FAX CENTER****JAN 12 2005**

In re Application of: _____X

S. Chackalamannil et al

Examiner: Rita J. Desai

Serial No.: 10/671,216

Group Art Unit: 1625

Filed: 09/25/2003

Atty. Docket No.: CV01185K1BK

For: "Thrombin Receptor Antagonists" _____X

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

Sir:

Petitioner, Schering Corporation, is the owner of 100% interest in the instant application. Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 36 U.S.C. sections 154 to 156 and 173, as presently shortened by any terminal disclaimer, of commonly-owned U.S. Patent Application, Serial No. 10/457,256. Petitioner hereby agrees that any patent granted on the instant application shall be enforceable only for and during such period that it and any of the aforesaid patent application are commonly-owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the fully statutory term as defined in 35 U.S.C. sections 154 to 156 and 173 of the aforesaid patent application, as presently shortened by any terminal disclaimer, in the event that either one or both later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Petitioner is the owner of 100% interest in the instant application by virtue of an assignment to Schering Corporation from all the inventors, which

Case No. CV01185K1BK US

was recorded on September 10, 2001 in the U.S. Patent and Trademark Office at Reel 012158, Frame 0193.


The undersigned Attorney of Record states that he is empowered to act on behalf of the petitioner.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the instant or aforesaid applications or any patents issued thereon.

The USPTO is hereby authorized to charge the \$130 fee under 37 C.F.R. §1.20(d) for the present Terminal Disclaimer to charge account 19-0365. A duplicate of this document is enclosed for your records.

January 12, 2005
Schering-Plough Corporation
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, New Jersey 07033
Tel: 908-298-2960
Fax: 908-298-5388

Respectfully submitted,



Gerard E. Reinhardt
Reg. No. 43,041
Attorney for Applicant

49068-1

PATENT CASE: CV01185K1BK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**RECEIVED
CENTRAL FAX CENTER****JAN 12 2005**-----X
In re Application of:**S. Chackalamannil et al**

: Examiner: Rita J. Desai

Serial No.: **10/671,216**

: Group Art Unit: 1625

Filed: **09/25/2003**

: Atty. Docket No.: CV01185K1BK

For: **"Thrombin Receptor Antagonists"**
-----XCommissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450**TERMINAL DISCLAIMER**

Sir:

Petitioner, Schering Corporation, is the owner of 100% interest in the instant application. Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 36 U.S.C. sections 154 to 156 and 173, as presently shortened by any terminal disclaimer, of commonly-owned U.S. Patent No. 6,498,168. Petitioner hereby agrees that any patent granted on the instant application shall be enforceable only for and during such period that it and any of the aforesaid patent application are commonly-owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the fully statutory term as defined in 35 U.S.C. sections 154 to 156 and 173 of the aforesaid patent application, as presently shortened by any terminal disclaimer, in the event that either one or both later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Petitioner is the owner of 100% interest in the instant application by virtue of an assignment to Schering Corporation from all the inventors, which

was recorded on March 27, 1996, in the U.S. Patent and Trademark Office at Reel 7866, Frame 0202.


The undersigned Attorney of Record states that he is empowered to act on behalf of the petitioner.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the instant or aforesaid applications or any patents issued thereon.

The USPTO is hereby authorized to charge the \$130 fee under 37 C.F.R. §1.20(d) for the present Terminal Disclaimer to charge account 19-0365. A duplicate of this document is enclosed for your records.

January 12, 2005
Schering-Plough Corporation
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, New Jersey 07033
Tel: 908-298-2960
Fax: 908-298-5388

Respectfully submitted,


Gerard E. Reinhardt
Reg. No. 43,041
Attorney for Applicant

DUPLICATE

PATENT CASE: CV01185K1BK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: _____X

S. Chackalamannil et alSerial No.: **10/671,216**Filed: **09/25/2003**For: **"Thrombin Receptor Antagonists"** _____X

Examiner: Rita J. Desai

Group Art Unit: 1625

Atty. Docket No.: CV01185K1BK

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
CENTRAL FAX CENTER

JAN 12 2005

TERMINAL DISCLAIMER

Sir:

Petitioner, Schering Corporation, is the owner of 100% interest in the instant application. Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 36 U.S.C. sections 154 to 156 and 173, as presently shortened by any terminal disclaimer, of commonly-owned U.S. Patent No. 6,498,168. Petitioner hereby agrees that any patent granted on the instant application shall be enforceable only for and during such period that it and any of the aforesaid patent application are commonly-owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the fully statutory term as defined in 35 U.S.C. sections 154 to 156 and 173 of the aforesaid patent application, as presently shortened by any terminal disclaimer, in the event that either one or both later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Petitioner is the owner of 100% interest in the instant application by virtue of an assignment to Schering Corporation from all the inventors, which

Case No.CV01185K1BKUS

was recorded on March 27, 1996, in the U.S. Patent and Trademark Office at Reel 7866, Frame 0202.


The undersigned Attorney of Record states that he is empowered to act on behalf of the petitioner.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the instant or aforesaid applications or any patents issued thereon.

The USPTO is hereby authorized to charge the \$130 fee under 37 C.F.R. §1.20(d) for the present Terminal Disclaimer to charge account 19-0365. A duplicate of this document is enclosed for your records.

January 12, 2005
Schering-Plough Corporation
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, New Jersey 07033
Tel: 908-298-2960
Fax: 908-298-5388

Respectfully submitted,


Gerard E. Reinhardt
Reg. No. 43,041
Attorney for Applicant

49792-1

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.